A Study of ABI-H3733 for chronic Hepatitis B
The company Assembly Biosciences is commencing recruitment for the clinical trial of the A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection.
The trial officially began on the June 2022 and is planned to complete on January 2023.
This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-H3733 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis B e antigen (HBeAg) positive or negative. The study will enroll up to 5 sequential cohorts of 10 subjects each, for a total of up to 50 subjects, randomized 8:2 to receive ABI-H3733 or placebo.
The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05414981 or clinicaltrials.gov/ct2/show/NCT05414981.
